Association between CYP2C19*2/*3 Polymorphisms and Coronary Heart Disease

Abstract

This study sought to explore the relationship between cytochrome P450 2C19 (CYP2C19) *2/*3 polymorphisms and the development of coronary heart disease (CHD), and to evaluate the influence of the single nucleotide polymorphisms (SNPs) on the occurrence of adverse clinical events in CHD patients. A total of 231 consecutive patients candidate for percutaneous coronary intervention genotyped for CYP2C19*2 (681G>A) and *3 (636G>A) polymorphisms were enrolled. The adverse clinical events were recorded during a follow-up period of 14 months. The incidence of CHD, according to coronary angiography, was significantly higher (P=0.025) in CYP2C19*2 carriers group. Stepwise binary logistic regression analysis revealed that among factors that potentially influenced the presence of CHD (age>60 years, gender, BMI, etc.), CYP2C19*2 carriers (OR 1.94, 95% CI: 1.08–3.50, P=0.028) and male gender (OR 2.74, 95% CI: 1.58–4.76, P=0.001) were independent predictors, which were associated with the presence of CHD. The follow-up results showed that the incidence of adverse cardiovascular events within 14 months of discharge was significantly higher in the CYP2C19*2 carriers than in the non-carriers (21.6% vs. 6.3%, P=0.019). The results of the multivariate Cox proportional hazards model showed that CYP2C19*2 loss-of-function was the only independent factor which predicted the coronary events during the follow-up period of 14 months (OR=3.65, 95% CI 1.09–12.25, P=0.036). The adverse impact of CYP2C19*2 polymorphisms was found not only in the risk of the presence of CHD, but also in the adverse cardiovascular events in CHD patients during the follow-up period of 14 months. However the same influence was not found in CYP2C19*3 mutation in Chinese Han population.

Keywords

cytochrome P450 2C19 / polymorphisms / coronary heart disease / clopidogrel

References

[1] RomanRJ. P–450 metabolites of arachidonic acid in the control of cardiovascular function. J Physiol Rev, 2002, 82(1): 131-185

[2] OyekanAO, McAwardK, ConettaJ, et al.. Endothelin–1 and CYP450 arachidonate metabolites interact to promote tissue injury in DOCA–salt hypertension. Am J Physiol, 1999, 276(3): R775

[3] WuS, MoomawCR, TomerKB, et al.. Molecular cloning and expression of CYP2J2, a human cytochrome P450 arachidonic acid epoxygenase highly expressed in heart. J Biol Chem, 1996, 271(7): 3460-3468

[4] LinJHC, KobariY, ZhuY, et al.. Human umbilical vein endothelial cells express P450 2C8 mRNA: cloning of endothelial P450 epoxygenase. Endothelium, 1996, 4(3): 219-229

[5] Ingelman–SundbergM, SimSC, GomezA, et al.. Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther, 2007, 116(3): 496-526

[6] ErcanB, AyazL, CicekD, et al.. Role of CYP2C9 and CYP2C19 polymorphisms in patients with atherosclerosis. Cell Biochem Funct, 2008, 26(3): 309-313

[7] YangYN, WangXL, MaYT, et al.. Association of interaction between smoking and CYP 2C19*3 polymorphism with coronary artery disease in a Uighur population. Clin Appl Thromb Hemost, 2010, 16(5): 579-583

[8] FichtlschererS, DimmelerS, BreuerS, et al.. Inhibition of cytochrome P450 2C9 improves endotheliumdependent, nitric oxide–mediated vasodilatation in patients with coronary artery disease. Circulation, 2004, 109(2): 178-183

[9] ShinDJ, KwonJ, ParkAR, et al.. Association of CYP2C19*2 and *3 genetic variants with essential hypertension in Koreans. Yonsei Med J, 2012, 53(6): 1113-1119

[10] GasparyanAY, WatsonT, LipGY. The Role of Aspirin in Cardiovascular Prevention Implications of Aspirin Resistance. J Am Coll Cardiol, 2008, 51(19): 1829-1843

[11] HolmesDR, DehmerGJ, KaulS, et al.. ACCF/AHA Clopidogrel Clinical Alert: Approaches to the FDA “Boxed Warning”: A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the American Heart Association Endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. J Am Coll Cardiol, 2010, 56(4): 321-341

[12] SaviP, PereilloJM, UzabiagaMF, et al.. Identification and biological activity of the active metabolite of clopidogrel. Thromb Haemost, 2000, 84(5): 891-896

[13] MegaJL, CloseSL, WiviottSD, et al.. Cytochrome p–450 polymorphisms and response to clopidogrel. N Engl J Med, 2009, 360(4): 354-362

[14] ColletJP, HulotJS, PenaA, et al.. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet, 2009, 373(9660): 309-317

[15] ShuldinerAR, O’ConnellJR, BlidenKP, et al.. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA, 2009, 302(8): 849-857

[16] SimonT, VerstuyftC, Mary–KrauseM, et al.. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med, 2009, 360(4): 363-375

[17] FoodU D Administration. FDA Drug Safety Communication: Reduced effectiveness of Plavix (clopidogrel) in patients who are poor metabolizers of the drug. Drug Safety and Availability. Food and Drug Administration (United States), 2010

[18] MegaJL, SimonY, ColletJP, et al.. Reduced–function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta–analysis. JAMA, 2010, 304(16): 1821-1830

[19] PareG, MehtaSR, YusufS, et al.. Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. N Engl J Med, 2010, 363(18): 1704-1714

[20] HolmesMV, PerelP, ShahT, et al.. CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events. JAMA, 2011, 306(24): 2704-2714

[21] DestaZ, ZhaoX, ShinJG, et al.. Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet, 2002, 41(12): 913-958

[22] ManM, FarmenM, DumaualC, et al.. Genetic variation in metabolizing enzyme and transporter genes: comprehensive assessment in 3 major East Asian subpopulations with comparison to Caucasians and Africans. J Clin Pharmacol, 2010, 50(8): 929-940

[23] HunterAL, CruzRP, CheyneBM, et al.. Cytochrome p450 enzymes and cardiovascular disease. Can J Physiol Pharmacol, 2004, 82(12): 1053-1060

[24] KazuiM, NishiyaY, IshizukaT, et al.. Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab Dispos, 2010, 38(1): 92-99

[25] AngiolilloDJ, Fernández–OrtizA, BernardoE, et al.. High clopidogrel loading dose during coronary stenting: effects on drug response and interindividual variability. Eur Heart J, 2004, 25(21): 1903-1910

[26] BrandtJT, CloseSL, IturriaSJ, et al.. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J Thromb Haemost, 2007, 5(12): 2429-2436

[27] UmemuraK, FurutaT, KondoK. The common gene variants of CYP2C19 affect pharmacokinetics and pharmacodynamics in an active metabolite of clopidogrel in healthy subjects. J Thromb Haemostasis, 2008, 6(8): 1439-1441

[28] HulotJS, BuraA, VillardE, et al.. Cytochrome P450 2C19 loss–of–function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood, 2006, 108(7): 2244-2247

[29] GiustiB, GoriAM, MarcucciR, et al.. Cytochrome P450 2C19 loss–of–function polymorphism, but not CYP3A4 IVS10+ 12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high–risk vascular patients. Pharmacogenet Genomics, 2007, 17(12): 1057-1064

[30] TrenkD, HochholzerW, FrommMF, et al.. Cytochrome P450 2C19 681G>A polymorphism and high onclopidogrel platelet reactivity associated with adverse 1–year clinical outcome of elective percutaneous coronary intervention with drug–eluting or bare–metal stents. J Am Coll Cardiol, 2008, 51(20): 1925-1934

[31] FrereC, CuissetT, MorangePE, et al.. Effect of Cytochrome P450 Polymorphisms on Platelet Reactivity After Treatment With Clopidogrel in Acute Coronary Syndrome. Am J Cardiol, 2008, 101(8): 1088-1093

[32] WallentinL, JamesS, StoreyRF, et al.. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet, 2010, 376(9749): 1320-1328

[33] ParéG, MehtaSR, YusufS, et al.. Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. New Engl J Med, 2010, 363(18): 1704-1714